Prana initiates Phase IIa Huntington disease trial
Reach2HD is a double blind placebo controlled study enrolling 100 patients with early to mid-stage Huntington Disease. The six month study aims to demonstrate cognitive improvements as already
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has granted priority medicines (PRIME) designation to AbelZeta Pharma’s C-CAR168.